Make that seven losses in a row for the Chicago Bulls. To this group's credit, they avoided the kind of blowout loss Toronto handed them back on February 5. The effort level was high, but the ...

At the end of January, I wrote an article about the Kansas City Royals potentially moving a starting pitcher for prospects. The Royals have enviable depth, and I think there are six guys – Cole Ragans ...

Data centers face a conundrum: how to power increasingly dense server racks using equipment that relies on century-old technology. Traditional transformers are bulky and hot, but a new generation of ...

Scientists have long seen a puzzling pattern in tokamaks, the doughnut-shaped machines that could one day reliably generate electricity from fusing atoms. When plasma particles escape the core of the ...

With most of the Big Tech earnings reports behind us, widening concerns about the costs of the artificial intelligence boom are rattling markets and injecting a fresh dose of volatility into ...

Experts recommend you rotate your tires every 4,000 to 8,000 miles. While most drivers tend to stay on top of regular maintenance, there are a few important procedures they may overlook. Getting an ...

Women's Health may earn commission from the links on this page, but we only feature products we believe in. Why Trust Us? Our movement is not one-dimensional, so your workouts shouldn’t be either.

Per the terms of the agreement, Novavax will receive an upfront payment of $30 million from Pfizer and is eligible to earn up to $500 million in potential development and commercial milestone payments ...

Novavax secures a non-exclusive licensing deal with Pfizer, validating Matrix-M's platform value and shifting NVAX toward a technology provider model. NVAX receives $30M upfront, a potential $500M in ...

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments. The biotech company said ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine programs. The tech, called Matrix-M, is designed to trigger an immune ...